MedTrace Logo

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

NCT02016833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2015-04-30

No results posted yet for this study

Summary

This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients. Such a study will allow the development of suitable immunological tools to be used in assessing response in a subsequent phase I study aiming at evaluating therapeutic vaccine candidates targeting WT-1, Survivin and/or HPV16 E7-expressing tumors. In addition, this study will help defining the baseline cancer-associated immune responses in the selected patient population.

Cervical and ovarian cancer patients, as well as leukemia patients, will be included in this study.

WT-1, Survivin and HPV-specific immune responses will be monitored in these patients by ex vivo and cultured IFNg ELISpot as well as tetramer staining.

Conditions

Interventions

PROCEDURE

Blood Sampling

Sampling of 80mL of whole blood

Sponsors & Collaborators

  • PX Biosolutions

    lead INDUSTRY

Principal Investigators

  • Linda Mileshkin, MD · Peter MacCallum Cancer Centre, Australia

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-06-30
Completion
2014-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02016833 on ClinicalTrials.gov